Skip to main content
Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc. — Investor Relations & Filings

Ticker · LYRA ISIN · US55234L1052 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2023-04-25 Proxy Solicitation & In…
Country US United States of America
Listing US LYRA

About Lyra Therapeutics, Inc.

https://lyratherapeutics.com/

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company that develops and commercializes innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). The company's product candidates are long-acting, anti-inflammatory sinonasal implants designed to deliver medication directly to sinonasal tissues. This approach aims to provide a new, long-lasting treatment option for patients with this debilitating inflammatory disease, targeting tissues that are not easily accessible with conventional therapeutic methods.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement related to shareholder voting matters. It includes information about the upcoming Annual Meeting, voting instructions, and proposals such as election of directors and appointment of auditors. The document is titled 'Definitive Additional Materials' for the proxy statement and does not contain financial statements or detailed management discussion. It is not the proxy statement itself but additional materials related to the proxy. Given the content and the SEC form type, the most appropriate classification is 'Proxy Solicitation & Information Statement' (PSI). The document length is under 5,000 characters and focuses on voting materials, consistent with PSI filings.
2023-04-25 English
DEF 14A Filing
Proxy Solicitation & Information Statement
2023-04-25 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans. It includes details about the registration of additional shares under specific award plans, references to prior registration statements, and legal indemnification provisions. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. The document is lengthy (15,000 characters) and contains no financial statements or earnings data. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for filings that do not fit other specific categories.
2023-03-29 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 29, 2023, by Lyra Therapeutics, Inc. It announces the company's financial results for the year ended December 31, 2022, and includes a press release (Exhibit 99.1) described as the Q4 2022 Earnings Release. Additionally, it attaches a corporate presentation (Exhibit 99.2). The key content is the announcement of financial results, which aligns with an Earnings Release (ER). The document is not the full annual report (10-K) but a current report announcing quarterly/year-end results. The length is 4223 characters, which is typical for an 8-K earnings release filing. Therefore, the best classification is Earnings Release (ER).
2023-03-29 English
10-K Filing
Annual Report FY 2022
2023-03-29 English
FORM 4 SUBMISSION
Director's Dealing
2023-02-28 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.